E-LIB Suche - Ergebnisse für: Reshetnyak, T.

1

Augmentation du risque thrombotique chez les patients SAPL ..:

Dufrost, V. ; Reshetnyak, T. ; Satybaldyeva, M....
JMV-Journal de Médecine Vasculaire. 44 (2019) 2 - p. 138 , 2019

Link: https://doi.org/10.1016/..

2

Antibodies to prothrombin in patients with Sneddon's syndro..:

Kalashnikova, L.A. ; Korczyn, A.D. ; Shavit, S....
Neurology. 53 (1999) 1 - p. 223-223 , 1999

Link: https://doi.org/10.1212/..

3

Erratum to: Antibodies to Domain I β2-Glycoprotein 1 in Pat..:

Reshetnyak, T. M. ; Cheldieva, F. A. ; Cherkasova, M. V....
Doklady Biochemistry and Biophysics. 513 (2023) 1 - p. 358-358 , 2023

Link: https://doi.org/10.1134/..

4

Erratum to: Global Antiphospholipid Syndrome Score (GAPSS) ..:

Cheldieva, F. A. ; Reshetnyak, T. M. ; Shumilova, A. A....
Doklady Biochemistry and Biophysics. 513 (2023) 1 - p. 360-360 , 2023

Link: https://doi.org/10.1134/..

5

Global Antiphospholipid Syndrome Score (GAPSS) in Patients ..:

Cheldieva, F. A. ; Reshetnyak, T. M. ; Shumilova, A. A....
Doklady Biochemistry and Biophysics. 511 (2023) 1 - p. 227-234 , 2023

Link: https://doi.org/10.1134/..

6

Antibodies to Domain I β2-Glycoprotein 1 in Patients with A..:

Reshetnyak, T. M. ; Cheldieva, F. A. ; Cherkasova, M. V....
Doklady Biochemistry and Biophysics. 511 (2023) 1 - p. 219-226 , 2023

Link: https://doi.org/10.1134/..

7

Mental disorders and cognitive impairment in patients with ..:

Borisova, A. B. ; Lisitsyna, T. A. ; Veltishchev, D. Yu....
Terapevticheskii arkhiv. 92 (2020) 5 - p. 92-103 , 2020

Link: https://doi.org/10.26442..

8

Effectiveness and safety of selective and non - selective f..:

Seredavkina, N V ; Reshetnyak, T M ; Satybaldyeva, M A...
Terapevticheskii arkhiv. 91 (2019) 5 - p. 19-25 , 2019

Link: https://doi.org/10.26442..

9

Chronic thromboembolic pulmonary hypertension developed in ..:

Movsisyan, G A ; Martynyuk, T V ; Mershin, K V...
Terapevticheskii arkhiv. 89 (2017) 9 - p. 93-99 , 2017

Link: https://doi.org/10.17116..

10

Polymorphism of the plasminogen activator inhibitor type 1 ..:

Aisina, R. B. ; Mukhametova, L. I. ; Ostryakova, E. V....
Biochemistry (Moscow) Supplement Series B: Biomedical Chemistry. 7 (2013) 1 - p. 1-15 , 2013

Link: https://doi.org/10.1134/..

11

LONG-TERM OBSERVATION OF 280 PATIENTS WITH SYSTEMIC LUPUS E..:

Reshetnyak, T.M. ; Alexandrova, E.N. ; Stivelband, I.B...
Journal of Thrombosis and Haemostasis. 5 (2007) - p. P-T-430-P-T-430 , 2007

Link: https://doi.org/10.1111/..

12

Minimax approach to forecasting individual economic indicat..:

Nurminskii, E. A. ; Reshetnyak, T. V.
Cybernetics. 11 (1976) 3 - p. 499-500 , 1976

Link: https://doi.org/10.1007/..

13

Effect of Additional Treatments Combined with Conventional ..:

Ruffatti, A ; Tonello, M ; Hoxha, A...
Thromb Haemost. 2018 Apr;118(4):639-646.. , 2018

Link: http://hdl.handle.net/10..

14

Erratum to: Antibodies to Domain I β2-Glycoprotein 1 in Pat..:

Reshetnyak, T. M ; Cheldieva, F. A ; Cherkasova, M. V...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10808236/. , 2024

Link: http://www.ncbi.nlm.nih...

15

Erratum to: Global Antiphospholipid Syndrome Score (GAPSS) ..:

Cheldieva, F. A ; Reshetnyak, T. M ; Shumilova, A. A...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10808370/. , 2024

Link: http://www.ncbi.nlm.nih...